April 19, 2026
Trump-backed plan could fast-track psychedelic therapies — here's what to know
President Trump has signed an executive order to fast-track psychedelic research and FDA approval, sparking debate among doctors over safety and mental health benefits.
TL;DR
- President Trump signed an executive order to fast-track research, funding, and FDA approval of psychedelic drugs for mental health conditions like PTSD, depression, and addiction.
- Supporters believe this move could provide life-saving treatments for veterans and others suffering from treatment-resistant conditions.
- Critics, however, warn about limited evidence on safety and effectiveness, citing concerns about drugs like ibogaine which remain Schedule I substances with serious safety risks.
- Experts agree that while psychedelics show potential, further research is needed to establish proper dosages, indications, and ensure safe administration in controlled clinical settings by trained providers.
- Concerns include cardiotoxicity risks associated with ibogaine and the potential for psychosis or anxiety disorders from improper use.